The global Rare Disease Genetic Testing Market size was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.5 billion in 2026 to USD 3.9 billion by 2033, registering a CAGR of 14.9% from 2026 to 2033. North America accounted for the largest revenue share of 46.7% in 2025, supported by advanced genomic research, widespread adoption of next-generation sequencing (NGS), favorable reimbursement policies, and the presence of leading molecular diagnostics companies.

The market is experiencing rapid expansion due to continuous advancements in next-generation sequencing (NGS) technologies, increasing awareness of rare genetic disorders, declining genome sequencing costs, and the growing adoption of precision medicine. Healthcare providers are increasingly utilizing comprehensive genetic testing to improve early diagnosis, identify disease-causing variants, and develop personalized treatment strategies for patients affected by rare inherited disorders.

Rare disease genetic testing has become an essential component of modern precision healthcare, particularly for patients with complex or undiagnosed conditions where conventional diagnostic methods often fail to provide accurate clinical answers. As genomic technologies continue to evolve, healthcare systems are increasingly integrating genetic testing into routine clinical practice to shorten diagnostic timelines and improve patient outcomes.

Market Dynamics & Industry Characteristics

The rare disease genetic testing industry is evolving rapidly through advances in genomics, bioinformatics, artificial intelligence, and molecular diagnostics.

Several key factors continue to drive market expansion, including:

• Growing adoption of next-generation sequencing (NGS)
• Increasing awareness of rare genetic disorders
• Rising demand for personalized medicine
• Expansion of patient registries
• Declining genome sequencing costs
• Advancements in bioinformatics and clinical decision support
• Growing investments in precision diagnostics
• One of the strongest growth drivers is the continued Increasing collaboration between healthcare institutions and genomic laboratories

Download a free sample copy of the Rare Disease Genetic Testing Market report to understand detailed coverage and inclusions in the final report

expansion of rare disease patient registries, which consolidate genomic information, phenotypic characteristics, clinical histories, and patient-reported outcomes into centralized databases.

These structured datasets enable researchers and clinicians to establish stronger genotype-phenotype correlations, improve variant interpretation, accelerate biomarker discovery, and enhance diagnostic accuracy for complex inherited disorders.

Emerging Industry Trend: AI-Driven Genomic Interpretation

Artificial intelligence is becoming increasingly important in rare disease diagnostics by assisting laboratories with automated variant classification, genomic interpretation, phenotype matching, and clinical decision support.

AI-powered bioinformatics platforms significantly reduce analysis time while improving diagnostic confidence, enabling laboratories to process larger testing volumes with greater efficiency. Combined with cloud-based genomic databases and machine learning algorithms, these technologies are expected to transform rare disease diagnostics over the coming decade.

Technology Outlook

Continuous technological innovation remains one of the primary growth catalysts for the rare disease genetic testing market.

The dramatic decline in genome sequencing costs has transformed genetic testing from an expensive research tool into an increasingly accessible clinical diagnostic solution. Advances in sequencing technologies and increasing market competition have significantly reduced testing costs while improving sequencing speed, accuracy, and scalability.

Modern diagnostic laboratories continue investing in:

• Automated sample processing
• High-throughput sequencing platforms
• Advanced bioinformatics pipelines
• AI-assisted variant interpretation
• Continuous genomic data reanalysis
• Integrated clinical decision support systems

Among available technologies, whole exome sequencing (WES) and whole genome sequencing (WGS) have become indispensable for identifying pathogenic variants associated with rare inherited disorders. These technologies enable comprehensive analysis of large genomic regions with greater diagnostic precision than conventional testing methods.

Key Market Trends & Insights

Neurological Disorders Lead Disease Segmentation

• By disease, the neurological disorders segment accounted for the largest market share of 29.1% in 2025.
• Rare neurological disorders often exhibit overlapping clinical symptoms, making traditional diagnosis highly challenging.
• Advanced genetic testing enables clinicians to accurately identify disease-causing variants, significantly improving diagnostic confidence and treatment planning.

Next-Generation Sequencing Dominates Technology

• By technology, the next-generation sequencing (NGS) segment held the largest market share of 57.1% in 2025.
• Continuous improvements in sequencing platforms, genomic interpretation software, and bioinformatics tools have substantially expanded the clinical utility of NGS.
• High-throughput sequencing enables faster, more comprehensive identification of pathogenic variants responsible for rare inherited disorders.

Looking for more specific insights? Customize this report to suite your business needs

Molecular Genetic Tests Experience Strong Growth

• By specialty, the molecular genetic tests segment held the largest market share in 2025 and is expected to register the fastest CAGR during the forecast period.
• Rising adoption of precision medicine, increasing global research collaborations, and ongoing innovation in molecular diagnostics continue to drive segment expansion.
• Strategic collaborations between diagnostic companies are accelerating the development of advanced companion diagnostics and expanding access to precision genomic testing worldwide.

Diagnostic Laboratories Lead End Use

• By end use, the diagnostic laboratories segment accounted for the largest market share in 2025.
• Specialized laboratories provide comprehensive genetic testing services for hospitals, research institutions, and healthcare providers.
• Investments in automation, multiplex testing, bioinformatics, and genetic counseling continue to improve laboratory throughput, diagnostic accuracy, and clinical interpretation capabilities.

Regional Highlights

• Largest Regional Market: North America accounted for 46.7% of global revenue in 2025, driven by advanced healthcare infrastructure, genomic research leadership, and high adoption of precision medicine.
• Fastest Growing Region: Asia Pacific is expected to experience rapid growth during the forecast period owing to expanding genomic research programs, increasing healthcare investments, and rising awareness of rare diseases.
• Leading Country: The United States held the largest market share in 2025 due to strong investments in molecular diagnostics, favorable reimbursement policies, and the presence of major genetic testing companies.

Market Size & Forecast

• Market Size (2025): USD 1.3 Billion
• Estimated Market Size (2026): USD 1.5 Billion
• Projected Market Size (2033): USD 3.9 Billion
• CAGR (2026–2033): 14.9%

Industry Outlook

Rare diseases collectively affect more than 300 million people worldwide, including approximately 25–30 million individuals in the United States. Despite significant advances in genomic medicine, the average diagnostic journey for many patients still exceeds six years, while only around 40% of patients receive a confirmed diagnosis.

Approximately 80% of rare diseases have a genetic origin, and nearly half of diagnosed patients are children, emphasizing the growing need for faster, more accurate, and accessible genetic testing solutions.

Increasing adoption of genomic sequencing, AI-powered diagnostics, precision medicine initiatives, and collaborative international research programs is expected to significantly improve diagnostic rates while reducing diagnostic delays for patients with rare inherited disorders.

Competitive Landscape

The rare disease genetic testing market remains highly competitive, with companies investing heavily in genomic innovation, advanced sequencing technologies, molecular diagnostics, and strategic collaborations to strengthen their market position.

Key strategic priorities across the industry include:

• Next-generation sequencing innovation
• AI-enabled genomic analysis
• Precision medicine solutions
• Global laboratory expansion
• Strategic research collaborations
• Companion diagnostic development
• Bioinformatics platform enhancement
• Clinical genomics integration

Increasing partnerships between genomic technology providers, healthcare institutions, and pharmaceutical companies continue to accelerate innovation while expanding access to advanced genetic testing services globally.

Key Rare Disease Genetic Testing Company Insights

Leading market participants continue strengthening their competitive position through technological innovation, strategic partnerships, and expanded genomic testing capabilities.

Explore Grand View Horizon to see global and regional level statistics related to the Rare Disease Genetic Testing Market

Quest Diagnostics Inc.

Quest Diagnostics Inc. is one of the leading providers of diagnostic information services, offering an extensive portfolio of molecular diagnostics, genomic sequencing, hereditary disease testing, and precision medicine solutions. The company continues investing in advanced laboratory technologies and bioinformatics capabilities to improve rare disease diagnosis and clinical decision-making.

Centogene N.V.

Centogene N.V. specializes in rare disease diagnostics, combining genomic sequencing with extensive biodata and clinical information to improve disease identification and accelerate precision medicine. Its integrated database supports variant interpretation, biomarker discovery, and pharmaceutical research while enabling more accurate diagnosis of rare inherited disorders.

Key Rare Disease Genetic Testing Companies

The following companies are among the leading participants operating in the global rare disease genetic testing market:

• Quest Diagnostics Inc.
• Centogene N.V.
• Invitae Corp.
• 3billion, Inc.
• Arup Laboratories
• Eurofins Scientific
• Strand Life Sciences
• Ambry Genetics
• Perkin Elmer, Inc.
• Realm IDX, Inc.
• Macrogen, Inc.
• Baylor Genetics
• Color Genomics, Inc.
• Health Network Laboratories
• PreventionGenetics
• Progenity, Inc.
• CooperSurgical, Inc.
• Fulgent Genetics Inc.
• Myriad Genetics, Inc.
• Laboratory Corporation of America Holdings
• Opko Health, Inc.
• Artemis DNA

Conclusion

The global rare disease genetic testing market is expected to witness robust growth as healthcare systems increasingly prioritize early diagnosis, precision medicine, and personalized treatment strategies for patients with rare inherited disorders. Continuous advancements in next-generation sequencing, declining genome sequencing costs, artificial intelligence-driven genomic interpretation, and expanding patient registries are significantly improving diagnostic capabilities and accelerating clinical adoption.

As genomic technologies become more affordable and accessible, healthcare providers and diagnostic laboratories will continue integrating advanced molecular testing into routine clinical practice. Companies investing in high-throughput sequencing, AI-powered bioinformatics, precision diagnostics, and global research collaborations will be well-positioned to capitalize on the rapidly expanding rare disease genetic testing market through 2033.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…